| Claire Mcchesney, AUD | |
|
415 Highland Avenue, Suite 2, Cheshire, CT 06410-2557 | |
| (203) 272-4512 | |
| (203) 272-4517 |
| Full Name | Claire Mcchesney |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 12 Years |
| Location | 415 Highland Avenue, Cheshire, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760720817 | NPI | - | NPPES |
| 000520 | Other | CT | LICENSE |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Prohealth Physicians Pc | 1355246950 | 236 |
News Archive
Cardiac resynchronization therapy with defibrillators (CRT-D) is appropriate for patients who have left ventricular dysfunction and require chronic ventricular pacing, based on the findings of an observational study that being presented March 26 that the 61st annual American College of Cardiology (ACC) scientific session.
Accountable Care Organizations - or ACOs - formed for the first time in 2011, designed to combat rising medical costs and provide more coordinated care to Medicare patients. But the savings have been inconsistent nationwide.
An innovative family of EPA-registered disinfecting products will be launched through a new direct selling company, it was announced today.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the "RNA Silencing: Mechanism, Biology, and Application" Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam's therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington's disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.
› Verified 8 days ago
| Provider Name | Prohealth Physicians Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1720194053 PECOS PAC ID: 1355246950 Enrollment ID: O20031205000602 |
News Archive
Cardiac resynchronization therapy with defibrillators (CRT-D) is appropriate for patients who have left ventricular dysfunction and require chronic ventricular pacing, based on the findings of an observational study that being presented March 26 that the 61st annual American College of Cardiology (ACC) scientific session.
Accountable Care Organizations - or ACOs - formed for the first time in 2011, designed to combat rising medical costs and provide more coordinated care to Medicare patients. But the savings have been inconsistent nationwide.
An innovative family of EPA-registered disinfecting products will be launched through a new direct selling company, it was announced today.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the "RNA Silencing: Mechanism, Biology, and Application" Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam's therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington's disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.
› Verified 8 days ago
| Provider Name | Ear Nose & Throat Institute Of Connecticut Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1316724891 PECOS PAC ID: 4284078296 Enrollment ID: O20240219000430 |
News Archive
Cardiac resynchronization therapy with defibrillators (CRT-D) is appropriate for patients who have left ventricular dysfunction and require chronic ventricular pacing, based on the findings of an observational study that being presented March 26 that the 61st annual American College of Cardiology (ACC) scientific session.
Accountable Care Organizations - or ACOs - formed for the first time in 2011, designed to combat rising medical costs and provide more coordinated care to Medicare patients. But the savings have been inconsistent nationwide.
An innovative family of EPA-registered disinfecting products will be launched through a new direct selling company, it was announced today.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the "RNA Silencing: Mechanism, Biology, and Application" Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam's therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington's disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Claire Mcchesney, AUD 415 Highland Avenue, Suite 2, Cheshire, CT 06410-2557 Ph: (203) 272-4512 | Claire Mcchesney, AUD 415 Highland Avenue, Suite 2, Cheshire, CT 06410-2557 Ph: (203) 272-4512 |
News Archive
Cardiac resynchronization therapy with defibrillators (CRT-D) is appropriate for patients who have left ventricular dysfunction and require chronic ventricular pacing, based on the findings of an observational study that being presented March 26 that the 61st annual American College of Cardiology (ACC) scientific session.
Accountable Care Organizations - or ACOs - formed for the first time in 2011, designed to combat rising medical costs and provide more coordinated care to Medicare patients. But the savings have been inconsistent nationwide.
An innovative family of EPA-registered disinfecting products will be launched through a new direct selling company, it was announced today.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the "RNA Silencing: Mechanism, Biology, and Application" Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam's therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington's disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.
› Verified 8 days ago
Dr. Christina A Lee, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 415 Highland Ave Ste 2, Cheshire, CT 06410 Phone: 203-272-4512 Fax: 203-272-4517 | |
Dr. Judith Orrill Shea, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 415 Highland Ave, Suite 2, Cheshire, CT 06410 Phone: 203-272-4512 Fax: 203-272-4517 | |
Alexandra Morena Burgess, AU.D Audiologist Medicare: Accepting Medicare Assignments Practice Location: 415 Highland Ave Ste 2, Cheshire, CT 06410 Phone: 203-272-4512 Fax: 203-272-4517 | |
Comprehensive Hearing, Llc Audiologist Medicare: Not Enrolled in Medicare Practice Location: 415 Highland Ave, Cheshire, CT 06410 Phone: 203-272-4512 Fax: 203-272-4517 | |
Comprehensive Hearing Care Center, Llc Audiologist Medicare: Not Enrolled in Medicare Practice Location: 415 Highland Ave, Suite 2, Cheshire, CT 06410 Phone: 203-272-4512 Fax: 203-272-4517 |